Cite
HARVARD Citation
Xiu, M. et al. (2022). Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis. International journal of cancer. 151 (4), pp. 578-589. [Online].